R REPLIGEN CORP
| Market Cap | $6.92B |
| P/E Ratio | 142.90 |
| Forward P/E | 48.75 |
| Dividend Yield | — |
| Beta | 1.18 |
| 52W Range | $102.97 - $175.77 |
| # Hedge Funds | 0 |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
Hedge Fund Ownership
| Investor 0 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|
Insider Trading
| Insider Name of the company insider who made the trade 17 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| DAWES KAREN A | Sale | 275 | $161.00 | $44.27K | 17 Dec 2025 | 18 Dec 2025 |
| Loeillot OlivierChief Executive Officer | Sale | 7,041 | $170.00 | $1.20M | 25 Nov 2025 | 26 Nov 2025 |
| Olivier LoeillotChief Executive Officer | Sale | 7,041 | $170.00 | $1.20M | 25 Nov 2025 | 26 Nov 2025 |
| Bylund JamesChief Operating Officer | Sale | 2,191 | $151.21 | $331.30K | 18 Nov 2025 | 19 Nov 2025 |
| James BylundChief Operating Officer | Sale | 2,191 | $151.21 | $331.30K | 18 Nov 2025 | 19 Nov 2025 |
| Hunt Anthony | Sale | 3,000 | $155.45 | $466.35K | 13 Nov 2025 | 14 Nov 2025 |
| Hunt Anthony | Sale | 1,784 | $151.01 | $269.40K | 13 Nov 2025 | 14 Nov 2025 |
| Hunt Anthony | Sale | 1,956 | $157.11 | $307.31K | 13 Nov 2025 | 14 Nov 2025 |
| Hunt Anthony | Sale | 5,737 | $156.22 | $896.23K | 13 Nov 2025 | 14 Nov 2025 |
| Hunt Anthony | Sale | 2,500 | $154.32 | $385.80K | 13 Nov 2025 | 14 Nov 2025 |
| Hunt Anthony | Sale | 2,923 | $153.14 | $447.63K | 13 Nov 2025 | 14 Nov 2025 |
| Hunt Anthony | Sale | 2,100 | $152.17 | $319.56K | 13 Nov 2025 | 14 Nov 2025 |
| Hunt Anthony | Sale | 11,096 | $158.01 | $1.75M | 12 Nov 2025 | 13 Nov 2025 |
| Hunt Anthony | Sale | 464 | $158.51 | $73.55K | 12 Nov 2025 | 13 Nov 2025 |
| Hunt Anthony | Sale | 4,959 | $156.65 | $776.83K | 12 Nov 2025 | 13 Nov 2025 |
| Hunt Anthony | Sale | 4,740 | $155.85 | $738.73K | 12 Nov 2025 | 13 Nov 2025 |
| Hunt Anthony | Sale | 3,741 | $154.92 | $579.56K | 12 Nov 2025 | 13 Nov 2025 |
Frequently Asked Questions
What is RGEN stock price today?
REPLIGEN CORP (RGEN) is currently trading at $122.89. The stock has a 52-week range of $102.97 to $175.77 and a market capitalization of $6.92B.
Is RGEN a good stock to buy in 2026?
REPLIGEN CORP has a P/E ratio of 142.9 (forward P/E: 48.8), a dividend yield of none, and 1-year performance of -10.8%. 0 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling RGEN stock?
There have been 17 insider transactions for RGEN in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has RGEN stock performed over the past year?
REPLIGEN CORP (RGEN) has returned -10.8% over the past 12 months. The stock traded between $102.97 and $175.77 during this period, and is currently at $122.89.
Which hedge funds own RGEN (REPLIGEN CORP)?
0 tracked hedge funds currently hold RGEN in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is RGEN's market cap and valuation?
REPLIGEN CORP (RGEN) has a market capitalization of $6.92B. The trailing P/E ratio is 142.9 and forward P/E is 48.8. The stock is classified in the Healthcare sector.
What is RGEN's revenue and profitability?
REPLIGEN CORP reported revenue of $738.26M with net income of $48.89M and a profit margin of 0.07%. The stock has a beta of 1.18.
What sector is RGEN in and who are its biggest institutional holders?
REPLIGEN CORP (RGEN) operates in the Healthcare sector. It is held by 0 tracked hedge funds. See the ownership table above for the complete list.